Short answer
Altimmune, Inc. (ALT) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $5,000 (up 0.0% year over year) with net income of −$19M.
Q3 2025 key financials · XBRL
- Revenue
- $5,000
- +0.0% YoY · +0.0% QoQ
- Net income
- −$19M
- +16.8% YoY · +14.1% QoQ
- Operating margin
- -417180.0%
- EPS (diluted)
- −$0.21
- +34.4% YoY · +22.2% QoQ
Source: XBRL data from the Altimmune, Inc. (ALT) Q3 2025 10-Q on SEC EDGAR. USD.
Altimmune, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $5,000, flat YoY; no product sales generated
- Operating loss $20.9M vs $24.8M YoY; operating margin not disclosed
- MASH R&D $4.3M, down 48%; AUD R&D $1.9M and ALD R&D $1.5M
- Cash, equivalents, restricted cash and investments $210.8M; operating cash use $48.1M
- Financing provided $125.7M, including $111.8M equity proceeds and $14.3M term-loan proceeds
- Funding sufficient for at least twelve months; additional financing and partnerships needed long term
Risk Factors
- No material changes from 10-K risk factors filed February 27, 2025
- No newly triggered risk factor identified in the quarter
- Carried-forward risks unchanged from latest 10-Q filed August 12, 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Altimmune, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.